
Baxter Ventures invests €2m in Zytoprotec
Baxter Ventures has invested €2m as part of a €4m series-A round for Vienna-based biotech company Zytoprotec.
The company has just completed a phase I/II trial for its lead product PD-protec, a next-generation solution for peritoneal dialysis (PD), and plans to enter a phase II trial following the transaction.
Baxter Ventures was established by Baxter International in 2011 to invest up to $200m in new businesses.
Company
Zytoprotec is a biotech company founded in Vienna in 2007. The business develops drugs by exploiting active cytoprotection as a novel therapeutic approach. It has established a research platform for the identification of cytoprotective compounds.
Prior to Baxter's funding, the company raised €6.7m from its founders, corporate, private and institutional investors, as well as Austrian public agencies.
People
Baxter chief science and innovation officer Norbert Riedel will join Zytoprotec's supervisory board as part of the transaction.
Advisers
Company - Wolf Theiss (Legal).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater